Get the Stockscreener App
2.29
0.43%
-0.010
Lexicon Pharmaceuticals Inc stock is traded at $2.29, with a volume of 1.68M.
It is down -0.43% in the last 24 hours and up +3.15% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$2.30
Open:
$2.3
24h Volume:
1.68M
Relative Volume:
0.52
Market Cap:
$1.02B
Revenue:
$69.64M
Net Income/Loss:
$-26.09M
P/E Ratio:
-32.03
EPS:
-0.0715
Net Cash Flow:
$-38.80M
1W Performance:
-4.18%
1M Performance:
+3.15%
6M Performance:
+34.71%
1Y Performance:
+102.65%
1-Day Range:
$2.24
$2.345
1-Week Range:
$2.19
$2.42
52-Week Range:
$1.00
$2.68
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.29 | 1.02B | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Price to earnings forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Enterprise value to EBITDA forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Price to book forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st
Lexicon Pharmaceuticals outlines its path in gastrointestinal disease. Drug pipeline and Nasdaq list - ad-hoc-news.de
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally - ChartMill
Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - AD HOC NEWS
Lexicon Pharmaceuticals (LXRX) Gains 3.88% as Stock Tests Key ResistanceStop Loss Guidance - DonanımHaber
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com
Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance
How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Hovers Near Key Support Amid Flat Trading SessionDark Pool Volume - dars.gov.et
Here's why you should add LXRX stock to your portfolio now - MSN
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 3000E Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000 Growth Benchmark - marketscreener.com
LXRX Surges As Traders Pounce On Strong Breakout - StocksToTrade
LXRX Jumps As Traders Focus On Breakout Momentum - timothysykes.com
LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders - StocksToTrade
LXRX Climbs As Bulls Press Multi-Day Breakout - timothysykes.com
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 - Investing.com UK
Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX) - TradingView
LXRX Forecast — Price Target — Prediction for 2027 - TradingView
Lexicon Pharmaceuticals debuts HCM education booth at heart failure conference - Traders Union
Here's Why You Should Add LXRX Stock to Your Portfolio Now - TradingView
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Lexicon Pharmaceuticals StockSunday background on strategy and trials - AD HOC NEWS
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence - TradingKey
Lexicon Pharmaceuticals Inc - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 – DelveInsight | Grünenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith - Barchart.com
Lexicon Pharmaceuticals Stock Offering: Strategic Move to Boost R&D - timothysykes.com
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Insider Monkey
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
126,122 |
| SOBECKI CHRISTOPHER J | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
293,177 |
| Cheung Ivan | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
89,312 |
| BARKER SAM L | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
213,771 |
| Amouyal Philippe | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
374,486 |
| DEBBANE RAYMOND | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
1,995,498 |
| Artal Participations S.a r.l. | Director |
Apr 30 '26 |
Option Exercise |
0.00 |
20,421,735 |
0 |
175,156,062 |
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):